Many clinicians still consider CAR‑T as a “last resort,” but in our experience, that framing may unintentionally narrow options for patients. At Mary Bird Perkins Cancer Center in Baton Rouge, we believe CAR‑T is best thought of as a time‑sensitive, highly personalized treatment that may be the right next step for some patients, often sooner than clinicians expect. Our goal, therefore, is to make it easier for physicians to know when to start the conversation, because early referral preserves options and improves planning.
There is no single moment when CAR‑T becomes appropriate; it’s a clinical judgment based on several factors. Our specialists look at how the disease responds to current therapy, whether it’s relapsed or refractory, how quickly it’s progressing, and the patient’s overall health and organ function. Historically, many CAR‑T products were used after two or more prior lines of therapy, but today, indications and practice are evolving, so earlier consideration is increasingly common in some diseases. Practically speaking, CAR‑T requires time for evaluation, apheresis, manufacturing, and insurance review, so initiating the referral conversation earlier gives everyone more flexibility. Timing can make a meaningful difference in which patients are eligible.
CAR‑T is not a one‑size‑fits‑all treatment. Because the therapy is manufactured from a patient’s own T cells, factors such as T‑cell fitness, disease burden, prior treatments, and organ reserve all influence both safety and efficacy. Patients who are less frail and less heavily pretreated tend to tolerate the process better and have improved outcomes. We also consider caregiver support and the ability to adhere to the monitoring plan, because close follow‑up is essential in the weeks after infusion.
It is important to note that physicians don’t need to determine final eligibility before making a referral. The multidisciplinary team at Mary Bird Perkins will perform the detailed assessment: reviewing prior therapies, ordering baseline testing, and advising on whether bridging therapy or other measures are needed while we prepare the product. Patient selection is nuanced and highly individualized; that’s why specialist evaluation matters.
Delaying referral can unintentionally remove CAR‑T as an option. The pathway from referral to infusion includes several steps that take time: comprehensive evaluation, infectious disease and organ assessments, apheresis scheduling, manufacturing, and payer authorization. If a patient’s disease progresses rapidly or their performance status declines while these steps are underway, they may no longer be a candidate. Early referral allows our team to coordinate these pieces, recommend safe bridging strategies when appropriate, and plan for caregiver needs and monitoring. Physicians don’t have to know for certain that a patient will qualify before making a referral; we just want to start the conversation early.
Many of the myths about CAR-T are rooted in understandable concerns. For example, while CAR‑T can cause cytokine release syndrome and neurologic events, these risks are well‑recognized and managed by experienced teams with established protocols. In addition, CAR‑T was once reserved for very late lines of therapy. But indications and clinical practice are shifting in some areas, and earlier use is being explored where evidence supports it. Finally, physicians do not need to “prove” eligibility before referring—evaluation is part of what we do. The biggest barrier is often timing and awareness, not eligibility.
We see ourselves as collaborators, not replacements. When physicians refer a patient, we aim to complement the care they are already providing: we evaluate candidacy, advise on timing and bridging options, coordinate testing and logistics, and keep referring physicians informed throughout the process. Early referral doesn’t mean handing off care. It means working together to preserve options and make the best possible plan for the patient.
If you’re managing a patient with relapse, refractory disease, or rapid progression, consider initiating a referral conversation now. Even if you’re unsure whether CAR‑T is the right choice, starting the evaluation gives us time to assess and advise. Early referral also allows for more flexibility and better planning. We’re here to help evaluate, guide, and collaborate, so you don’t have to navigate this decision alone.
Right here in Baton Rouge
CAR‑T therapy is a transformative option for select patients with B‑cell lymphoma, and its availability in Baton Rouge expands regional access to advanced cancer care. Mary Bird Perkins Cancer Center is committed to partnering with referring physicians through expert evaluation, outpatient delivery, and coordinated transitions back to local care.
To initiate a referral, please include recent clinical notes, pathology, and treatment history when available.
For assistance or more information on referring a patient, contact Shannon Hyde at shyde@marybird.com.
Early referral preserves options. Mary Bird Perkins stands ready to collaborate at every step, bringing advanced CAR‑T therapy closer to home for patients across the region.
